Want to see TNDM full AI Analyst Report?
TNDM Stock Chart & Stats
$20.61
-$0.45(-1.21%)
At close: 4:00 PM EST
$20.61
-$0.45(-1.21%)
Day’s Range― - ―
52-Week Range$9.98 - $29.65
Previous CloseN/A
Volume336.73K
Average Volume (3M)2.01M
Market Cap
$1.17B
Enterprise Value$1.48K
Total Cash (Recent Filing)$570.26M
Total Debt (Recent Filing)$734.74M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 06, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume1,426,444
30 Day Avg. Volume2,014,850
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.97Price Target Upside45.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ImprovementSustained, large top‑line growth (TTM +126%) with gross margin rising to ~55% and operating cash flow turning positive indicates improving product economics and stronger demand. These trends support durable margin sustainability and better internal funding for operations over the next several quarters.
Recurring Consumables And Installed BaseTandem’s core model—selling durable pumps that generate recurring consumable orders—creates high revenue visibility and customer stickiness. The installed base and >50% renewals on shipments (Q1) imply repeat demand, underpinning steady, durable revenue from supplies over multiple years.
Product, Regulatory And Integration MilestonesRegulatory wins and CGM integrations broaden addressable market (pregnancy clearance is unique), raise competitive differentiation, and deepen ecosystem lock‑in. Ongoing pipeline work (Mobi Tubeless 510(k), closed‑loop pivotal) supports durable future product launches and lifecycle revenue expansion.
Bears Say
Elevated Leverage And Thin Equity CushionMaterial increase in leverage with debt roughly $735M versus about $132M in equity leaves a thin capital cushion. High debt-to-equity magnifies downside risk if growth or margins weaken, constrains strategic flexibility, and raises refinancing or covenant risks over the medium term.
Ongoing Operating And Net LossesAlthough margins improved, the company remains unprofitable on operating and net bases. Persistent losses reduce retained earnings, depress returns on equity, and mean the business still depends on sustained revenue and margin progression or external capital to fully fund growth initiatives.
Supply Constraints And PayGo Transition FrictionCapacity limits at a key infusion‑set supplier and operational friction from shifting to pharmacy (PayGo) create durable execution risk for recurring consumable sales. These supply and channel transitions can restrain reorder volumes, slow pharmacy conversion, and delay expected scaling of lower‑cost distribution.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $29.65 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.17B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -$0.298 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.146.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.32.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.298 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went down -16.188%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.97 (45.40% Upside)
$29.97 (45.40% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 704.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.19%
12-Months-Change
Fundamentals
Return on Equity
-68.29%
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$29.97
▲(45.40% Upside)
Technical Analysis
Ownership Overview
0.99% Insiders
21.85% Mutual Funds
0.10% Other Institutional Investors
51.21% Public Companies and
Individual Investors